Synthesis and biological evaluation of 4-(aminomethyl)-1-hydroxypyrazole analogues of muscimol as γ-aminobutyric acid(a) receptor agonists. 2013

Jette G Petersen, and Rikke Bergmann, and Henriette A Møller, and Charlotte G Jørgensen, and Birgitte Nielsen, and Jan Kehler, and Karla Frydenvang, and Jesper Kristensen, and Thomas Balle, and Anders A Jensen, and Uffe Kristiansen, and Bente Frølund
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.

A series of bioisosteric 4-(aminomethyl)-1-hydroxypyrazole (4-AHP) analogues of muscimol, a GABA(A) receptor agonist, has been synthesized and pharmacologically characterized at native and selected recombinant GABA(A) receptors. The unsubstituted 4-AHP analogue (2a) (EC(50) 19 μM, R(max) 69%) was a moderately potent agonist at human α(1)β(2)γ(2) GABA(A) receptors, and in SAR studies substitutions in the 3- and/or 5-position were found to be detrimental to binding affinities. Ligand-receptor docking in an α(1)β(2)γ(2) GABA(A) receptor homology model along with the obtained SAR indicate that 2a and muscimol share a common binding mode, which deviates from the binding mode of the structurally related antagonist series based on 4-(piperidin-4-yl)-1-hydroxypyrazole (4-PHP, 1). Selectivity for α(1)β(2)γ(2) over ρ(1) GABA(A) receptors was observed for the 5-chloro, 5-bromo, and 5-methyl substituted analogues of 2a illustrating that even small differences in structure can give rise to subtype selectivity.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009118 Muscimol A neurotoxic isoxazole isolated from species of AMANITA. It is obtained by decarboxylation of IBOTENIC ACID. Muscimol is a potent agonist of GABA-A RECEPTORS and is used mainly as an experimental tool in animal and tissue studies. Agarin,Pantherine
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D058785 GABA-A Receptor Agonists Endogenous compounds and drugs that bind to and activate GABA-A RECEPTORS. GABA-A Agonists,GABA-A Receptor Agonist,Agonist, GABA-A Receptor,Agonists, GABA-A,Agonists, GABA-A Receptor,GABA A Agonists,GABA A Receptor Agonist,GABA A Receptor Agonists,Receptor Agonist, GABA-A,Receptor Agonists, GABA-A
D021241 Spectrometry, Mass, Electrospray Ionization A mass spectrometry technique used for analysis of nonvolatile compounds such as proteins and macromolecules. The technique involves preparing electrically charged droplets from analyte molecules dissolved in solvent. The electrically charged droplets enter a vacuum chamber where the solvent is evaporated. Evaporation of solvent reduces the droplet size, thereby increasing the coulombic repulsion within the droplet. As the charged droplets get smaller, the excess charge within them causes them to disintegrate and release analyte molecules. The volatilized analyte molecules are then analyzed by mass spectrometry. ESI Mass Spectrometry,Electrospray Ionization Mass Spectrometry,Mass Spectrometry, ESI,Spectrometry, ESI Mass

Related Publications

Jette G Petersen, and Rikke Bergmann, and Henriette A Møller, and Charlotte G Jørgensen, and Birgitte Nielsen, and Jan Kehler, and Karla Frydenvang, and Jesper Kristensen, and Thomas Balle, and Anders A Jensen, and Uffe Kristiansen, and Bente Frølund
September 2013, Bioorganic & medicinal chemistry,
Jette G Petersen, and Rikke Bergmann, and Henriette A Møller, and Charlotte G Jørgensen, and Birgitte Nielsen, and Jan Kehler, and Karla Frydenvang, and Jesper Kristensen, and Thomas Balle, and Anders A Jensen, and Uffe Kristiansen, and Bente Frølund
March 2020, Bioorganic & medicinal chemistry letters,
Jette G Petersen, and Rikke Bergmann, and Henriette A Møller, and Charlotte G Jørgensen, and Birgitte Nielsen, and Jan Kehler, and Karla Frydenvang, and Jesper Kristensen, and Thomas Balle, and Anders A Jensen, and Uffe Kristiansen, and Bente Frølund
March 2013, Journal of medicinal chemistry,
Jette G Petersen, and Rikke Bergmann, and Henriette A Møller, and Charlotte G Jørgensen, and Birgitte Nielsen, and Jan Kehler, and Karla Frydenvang, and Jesper Kristensen, and Thomas Balle, and Anders A Jensen, and Uffe Kristiansen, and Bente Frølund
January 2020, Bioorganic chemistry,
Jette G Petersen, and Rikke Bergmann, and Henriette A Møller, and Charlotte G Jørgensen, and Birgitte Nielsen, and Jan Kehler, and Karla Frydenvang, and Jesper Kristensen, and Thomas Balle, and Anders A Jensen, and Uffe Kristiansen, and Bente Frølund
June 1988, Journal of medicinal chemistry,
Jette G Petersen, and Rikke Bergmann, and Henriette A Møller, and Charlotte G Jørgensen, and Birgitte Nielsen, and Jan Kehler, and Karla Frydenvang, and Jesper Kristensen, and Thomas Balle, and Anders A Jensen, and Uffe Kristiansen, and Bente Frølund
January 2015, Bioorganic & medicinal chemistry,
Jette G Petersen, and Rikke Bergmann, and Henriette A Møller, and Charlotte G Jørgensen, and Birgitte Nielsen, and Jan Kehler, and Karla Frydenvang, and Jesper Kristensen, and Thomas Balle, and Anders A Jensen, and Uffe Kristiansen, and Bente Frølund
October 2009, Journal of medicinal chemistry,
Jette G Petersen, and Rikke Bergmann, and Henriette A Møller, and Charlotte G Jørgensen, and Birgitte Nielsen, and Jan Kehler, and Karla Frydenvang, and Jesper Kristensen, and Thomas Balle, and Anders A Jensen, and Uffe Kristiansen, and Bente Frølund
January 2023, Bioorganic & medicinal chemistry letters,
Jette G Petersen, and Rikke Bergmann, and Henriette A Møller, and Charlotte G Jørgensen, and Birgitte Nielsen, and Jan Kehler, and Karla Frydenvang, and Jesper Kristensen, and Thomas Balle, and Anders A Jensen, and Uffe Kristiansen, and Bente Frølund
November 2014, ChemMedChem,
Jette G Petersen, and Rikke Bergmann, and Henriette A Møller, and Charlotte G Jørgensen, and Birgitte Nielsen, and Jan Kehler, and Karla Frydenvang, and Jesper Kristensen, and Thomas Balle, and Anders A Jensen, and Uffe Kristiansen, and Bente Frølund
November 2011, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!